Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V

Journal of Clinical Oncology

Volumn 34, Issue 9, 2016, Pages 927-935

  Colleoni, Marco ^a   Sun, Zhuoxin ^c,d   Price, Karen N ^c   Karlsson, Per ^f   Forbes, John F ^g   Thürlimann, Beat ⁱ   Gianni, Lorenzo ^b   Castiglione, Monica ^j   Gelber, Richard D ^c,d,e   Coates, Alan S ^e,h   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OSPEDALE DEGLI INFERMI   (Italy)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^j International Breast Cancer Study Group   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR VOLUME; BREAST NEOPLASMS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; YOUNG ADULT;

EID: 84962068598     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.3504     Document Type: Article

References (35)

1. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746, 1996
2. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343: 377-381, 1994
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687-1717, 2005
4. Davies C, Godwin J, Gray R, et al.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378: 771-784, 2011
5. Peto R, Davies C, Godwin J, et al.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Comparisons between different poly-chemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432-444, 2012
6. McGale P, Taylor C, Correa C, et al.; EBCTCG (Early Breast Cancer Trialists' Collaborative Group): Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383: 2127-2135, 2014
7. Pagani O, Price KN, Gelber RD, et al.; International Breast Cancer Study Group (IBCSG): Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. Breast Cancer Res Treat 117: 319-324, 2009
8. Zhang XH, Giuliano M, Trivedi MV, et al: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19: 6389-6397, 2013
9. Sestak I, Dowsett M, Zabaglo L, et al: Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105: 1504-1511, 2013
10. Metzger-Filho O, Sun Z, Viale G, et al: Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX. J Clin Oncol 31: 3083-3090, 2013
11. Woods LM, Rachet B, Lambert PC, et al: "Cure" from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol 20: 1331-1336, 2009
12. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 5: 717-724, 1994
13. Ludwig Breast Cancer Study Group: Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle. N Engl J Med 319: 677-683, 1988
14. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491-496, 1989
15. Meakin JW, Hayward JL, Panzarella T, et al: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 37: 11-19, 1996
16. Jordan VC, Zava DT, Eppenburger U, et al: Reliability of steroid hormone receptor assays: An international study. Eur J Cancer Clin Oncol 19: 357-363, 1983
17. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141-1154, 1988
18. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509, 1999
19. Tubiana M, Koscielny S: Natural history of human breast cancer: Recent data and clinical implications. Breast Cancer Res Treat 18: 125-140, 1991
20. Brenner H, Hakulinen T: Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 22: 432-438, 2004
21. Bonadonna G, Moliterni A, Zambetti M, et al: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 330: 217-220, 2005
22. Green S: Do estimates of long-term survival tell us whether patients diagnosed with breast cancer before age 50 years are ever cured? J Clin Oncol 22: 392-394, 2004
23. Quesnel B: Tumor dormancy and immunoe-scape. APMIS 116: 685-694, 2008
24. Retsky MW, Demicheli R, Hrushesky WJ, et al: Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116: 730-741, 2008
25. Lim E, Metzger-Filho O, Winer EP: The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 26: 688-694, 696, 2012
26. Kim RS, Avivar-Valderas A, Estrada Y, et al: Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 7: e35569, 2012
27. Wikman H, Vessella R, Pantel K: Cancer micrometastasis and tumour dormancy. APMIS 116: 754-770, 2008
28. Gnant M, Filipits M, Greil R, et al.; Austrian Breast and Colorectal Cancer Study Group: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 risk of recurrence score in 1478 post-menopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25: 339-345, 2014
29. Khatcheressian JL, Wolff AC, Smith TJ, et al.; American Society of Clinical Oncology: American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24: 5091-5097, 2006
30. National Institute for Clinical Excellence. Guidance on cancer services: Improving outcomes in breast cancer - manual update. https://www.nice.org.uk/guidance/csg1/resources/improving-outcomes-in-breast-cancer-update-773371117
31. Dixon JM, Montgomery DA: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: The case for. Breast Cancer Res 10: S7, 2008 (suppl 4)
32. Cossetti RJ, Tyldesley SK, Speers CH, et al: Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 33: 65-73, 2015
33. Jatoi I, Anderson WF, Jeong JH, et al: Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J Clin Oncol 29: 2301-2304, 2011
34. Jeong JH, Jung SH, Wieand S: A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med 22: 339-352, 2003
35. Goldhirsch A, Winer EP, Coates AS, et al: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: 2206-2223, 2013